Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 15,000 shares of Opko Health stock in a transaction on Tuesday, September 19th. The shares were acquired at an average cost of $6.01 per share, with a total value of $90,150.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $18,444,395.51. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Monday, September 18th, Phillip Md Et Al Frost acquired 40,000 shares of Opko Health stock. The shares were purchased at an average cost of $6.00 per share, for a total transaction of $240,000.00.
  • On Friday, September 15th, Phillip Md Et Al Frost acquired 80,000 shares of Opko Health stock. The shares were purchased at an average cost of $6.01 per share, for a total transaction of $480,800.00.
  • On Thursday, September 14th, Phillip Md Et Al Frost acquired 260,000 shares of Opko Health stock. The shares were purchased at an average cost of $5.98 per share, for a total transaction of $1,554,800.00.
  • On Friday, August 25th, Phillip Md Et Al Frost acquired 25,000 shares of Opko Health stock. The shares were purchased at an average cost of $6.17 per share, for a total transaction of $154,250.00.
  • On Thursday, August 24th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The shares were purchased at an average cost of $6.24 per share, for a total transaction of $62,400.00.
  • On Wednesday, August 23rd, Phillip Md Et Al Frost acquired 12,000 shares of Opko Health stock. The shares were purchased at an average cost of $6.13 per share, for a total transaction of $73,560.00.
  • On Tuesday, August 22nd, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The shares were purchased at an average cost of $6.13 per share, for a total transaction of $11,034.00.
  • On Monday, August 21st, Phillip Md Et Al Frost acquired 25,000 shares of Opko Health stock. The shares were purchased at an average cost of $6.10 per share, for a total transaction of $152,500.00.
  • On Thursday, August 17th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The shares were purchased at an average cost of $5.96 per share, for a total transaction of $298,000.00.
  • On Wednesday, August 16th, Phillip Md Et Al Frost acquired 40,000 shares of Opko Health stock. The shares were purchased at an average cost of $6.04 per share, for a total transaction of $241,600.00.

Shares of Opko Health, Inc. (NASDAQ OPK) opened at 6.48 on Friday. The firm’s market cap is $3.62 billion. Opko Health, Inc. has a 1-year low of $5.85 and a 1-year high of $12.15. The company has a 50-day moving average of $6.19 and a 200-day moving average of $6.84.

Opko Health (NASDAQ:OPK) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.04) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. Opko Health had a negative return on equity of 3.67% and a negative net margin of 6.52%. The business had revenue of $314.20 million during the quarter, compared to analysts’ expectations of $322.64 million. During the same quarter in the prior year, the business earned $0.02 earnings per share. The company’s quarterly revenue was down 12.0% compared to the same quarter last year. Analysts predict that Opko Health, Inc. will post ($0.19) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/09/22/phillip-md-et-al-frost-buys-15000-shares-of-opko-health-inc-opk-stock.html.

A number of equities research analysts have recently commented on the stock. J P Morgan Chase & Co cut shares of Opko Health from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $12.00 to $7.00 in a research note on Thursday, September 14th. Cantor Fitzgerald assumed coverage on shares of Opko Health in a research note on Thursday, August 17th. They set an “overweight” rating and a $20.00 price objective on the stock. Zacks Investment Research cut shares of Opko Health from a “buy” rating to a “hold” rating in a research note on Saturday, August 12th. Jefferies Group LLC reaffirmed a “hold” rating and set a $6.50 price objective (down previously from $6.80) on shares of Opko Health in a research note on Thursday, August 10th. Finally, BidaskClub cut shares of Opko Health from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the stock. Opko Health presently has an average rating of “Hold” and an average price target of $14.36.

Several institutional investors have recently added to or reduced their stakes in OPK. BlackRock Inc. raised its stake in shares of Opko Health by 11,481.3% during the first quarter. BlackRock Inc. now owns 22,645,285 shares of the biotechnology company’s stock worth $181,163,000 after purchasing an additional 22,449,752 shares during the last quarter. State Street Corp raised its position in Opko Health by 40.3% in the first quarter. State Street Corp now owns 10,926,560 shares of the biotechnology company’s stock worth $87,412,000 after acquiring an additional 3,138,685 shares in the last quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management raised its position in Opko Health by 62.4% in the first quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management now owns 5,061,154 shares of the biotechnology company’s stock worth $40,489,000 after acquiring an additional 1,944,549 shares in the last quarter. Vanguard Group Inc. raised its position in Opko Health by 4.4% in the first quarter. Vanguard Group Inc. now owns 26,322,001 shares of the biotechnology company’s stock worth $210,576,000 after acquiring an additional 1,112,843 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ purchased a new position in Opko Health in the first quarter worth $4,450,000. Institutional investors and hedge funds own 22.46% of the company’s stock.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.